Who are Somatropin (rDNA origin)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Somatotropin growth hormone recombinant human.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/somatropin-rdna-origin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Somatropin (rDNA origin) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Somatropin (rDNA origin) (Somatropin (rDNA origin)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Growth hormone (recombinant). Area: Endocrinology.

phase 3 Growth hormone (recombinant) Growth hormone receptor (GHR) Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Somatropin (rDNA origin) (Somatropin (rDNA origin)) — Eli Lilly and Company. Somatropin is a recombinant human growth hormone that binds to growth hormone receptors to stimulate growth, metabolism, and body composition changes.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Somatropin (rDNA origin) TARGET	Somatropin (rDNA origin)	Eli Lilly and Company	phase 3	Growth hormone (recombinant)	Growth hormone receptor (GHR)
Somatotropin growth hormone recombinant human	Somatotropin growth hormone recombinant human	Rabin Medical Center	marketed	Growth hormone (recombinant)	Growth hormone receptor (GHR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Growth hormone (recombinant) class)

Eli Lilly and Company · 1 drug in this class
Rabin Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Somatropin (rDNA origin) — Competitive Intelligence Brief. https://druglandscape.com/ci/somatropin-rdna-origin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing